Gilmore Neil O'Neill - 12 Mar 2026 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Reporting relationship: CEO, Director
Issuer ticker: EDIT
Reported as of: 12 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Mar 2026, 16:37:09 UTC
Prior SEC filing: 04 Mar 2026
Next SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Gilmore O'Neill

Key filing fact

Gilmore Neil O'Neill filed Form 4 for Editas Medicine, Inc. (EDIT) on 16 Mar 2026.

Key facts

This page summarizes Gilmore Neil O'Neill's Form 4 filing for Editas Medicine, Inc. (EDIT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Mar 2026, 16:37.

Change

Previous filing in this sequence was filed on 04 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742084 Primary reporting owner

O'Neill Gilmore Neil

Relationship: CEO, Director
Address: C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE
Signature: /s/ Gilmore O'Neill
Signature date: 16 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EDIT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +1,015,200
Change %
Price: $0.000000^*
Shares after: 1,015,200
Date: 12 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,015,200
Exercise price: $2.54
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

This option was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments beginning on April 12, 2026 through March 12, 2030.